List view / Grid view
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
6 June 2016 | By Victoria White, Digital Content Producer
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency...
6 June 2016 | By Victoria White, Digital Content Producer
Immunocore has announced positive data from the first in human, Phase I clinical trial of its lead ImmTAC, IMCgp100...
6 June 2016 | By Victoria White, Digital Content Producer
POL6014 is a highly selective, potent and reversible inhibitor of hNE. Increased levels of hNE is associated with cystic fibrosis...
6 June 2016 | By Victoria White, Digital Content Producer
Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells...
6 June 2016 | By CPhI
The new Finished Dosage Formulation (FDF) event will be the first global pharma platform dedicated to the manufacture, development and supply of finished dosage forms...
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
6 June 2016 | By Victoria White, Digital Content Producer
Ganymed announced data from its randomised Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting...
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
6 June 2016 | By Victoria White, Digital Content Producer
New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
6 June 2016 | By Victoria White, Digital Content Producer
Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death...
3 June 2016 | By Victoria White, Digital Content Producer
Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody...
3 June 2016 | By Victoria White, Digital Content Producer
Shire and Baxalta have combined businesses, creating a leading global company focused on rare diseases and other highly specialised conditions...
3 June 2016 | By Victoria White, Digital Content Producer
The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer...
3 June 2016 | By Victoria White, Digital Content Producer
Three-year data show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors...
